In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 771-774

  Rodriguez Villalobos, Hector ^a   Malaviolle, Vincent ^a   Frankard, Joëlle ^a   de Mendonça, Ricardo ^a   Nonhoff, Claire ^a   Struelens, Marc J ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Antimicrobial susceptibility; E. coli; ESBLs

Indexed keywords

AGAR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; DNA; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BELGIUM; CONTROLLED STUDY; DILUTION; DNA SEQUENCE; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; ISOELECTRIC FOCUSING; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PROSPECTIVE STUDY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REFERENCE VALUE; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BELGIUM; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLINS;

EID: 33645120482     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl046     Document Type: Article

References (13)

1. Vanhoof R, Berin C, Carpentier M et al. Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals. Acta Clin Belg 2001; 56: 354-9.
2. National Committee for Clinical Laboratory Standards. (2001). Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard M100-S11. NCCLS, Wayne, PA, USA, 2001.
3. Fuchs PC, Barry AL, Thornsberry C et al. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 1985; 4: 30-3.
4. Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
5. Woodford N, Ward ME,Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
6. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
7. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.
8. Rodriguez-Villalobos H, Malaviolle V, Frankard J et al. Emergence of CTX-M extended spectrum β-lactamase-producing Escherichia coli in Belgium. EuroSurveillance Weekly 2005; 10: http://www.eurosurveillance.org.
9. Chanal M, Sirot J, Cluzel M et al. In vitro study of the bacteriostatic and bactericidal activity of temocillin(BRL17421). Pathol Biol (Paris) 1983; 31: 467-70.
10. Van Landuyt HW, Boelaert J, Piot P et al. In vitro activity of temocillin against clinical isolates. Drugs 1985; 29 Suppl 5: 1-8.
11. Verbist L. Temocillin sensitivity of Enterobacteriaceae species resistant to cefotaxime. Drugs 1985; 29 Suppl 5: 38-42.
12. Van Landuyt HW, Pyckavet M, Lambert A et al. In vitro activity of temocillin (BRL 17421), a novel β-lactam antibiotic. Antimicrob Agents Chemother 1982; 22: 535-40.
13. Williams JD, Chen HY. The place of temocillin in the treatment of hospital infections. Drugs 1985; 29 Suppl 5: 234-9.